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A pandemic of the 2009 H1N1 inﬂ  uenza A virus infection 
occurred worldwide in 2009. Some previously healthy 
patients experienced rapidly progressive pneumonia 
leading to acute respiratory distress syndrome (ARDS) 
and even death. Th  e eﬀ  ect of corticosteroids on these 
severely aﬀ  ected patients is controversial because of a 
lack of controlled clinical trials [1].
During the pandemic in South Korea, we observed that 
early, short-term cortico  steroid treatment along with 
oseltamivir seemed to have a dramatic eﬀ  ect on patients 
with severe pneumonia, and we proposed a new theory 
for the pathogenesis of acute lung injury in inﬂ  uenza 
virus infections [2]. In that study, we wanted to evaluate 
this beneﬁ  cial eﬀ  ect of cortico  steroid treatment through 
comparative data based on the use or non-use of 
corticosteroids at two separate hospitals. Th   e subjects of 
the study were the pneumonia patients who had severe 
respiratory distress with hypoxe  mia at presentation or 
during admission and who thus required oxygen therapy. 
Th   e conditions of 17 patients (median of 6 years of age, 
range of 4 to 9) in our hospital (Th   e Catholic University 
of Korea, Daejeon St Mary’s Hospital, Daejeon, South 
Korea) (use of corticosteroids) and 15 patients (median of 
6 years of age, range of 5 to 18) in a neighboring hospital 
(Chungnam National University Hospital, Daejeon, 
South Korea) (non-use of corticosteroids) were diag  nosed 
by reverse transcriptase-polymerase chain reac  tion. Th  e 
clinical and laboratory characteristics of patients in the 
two hospitals are shown in Table 1. Our results suggested 
that the severe pneumonia patients who were treated 
with cortico  steroids showed shortened durations of fever 
and oxygen therapy, rapid resolution of pneumonic 
inﬁ  ltrations, and possibly no progression to ARDS.
It is reported that corticosteroid treatment for adult 
ARDS patients with 2009 H1N1 virus infection was 
eﬀ  ective in the improvement of lung injury score [3]. Two 
recent case series suggest a possible life-saving role of 
corticosteroids in severely ill adult patients with 2009 
H1N1 virus infection unresponsive to other treatments 
[4,5]. Corticosteroids may not increase the viral load of 
the patients [4]. To the best of our knowledge, our study 
may be the ﬁ  rst trial addressing an early and preemptive 
modality before ARDS development in inﬂ  uenza virus 
infections. Our policy of corticosteroid treatment with a 
rapid, high-dose (methylprednisolone, 10 mg/kg per day), 
and short-term (tapered oﬀ   within a week) schedule did 
not show any complications in our patients and may 
avoid the complications that arise from long-term 
corticosteroid use.
Although rapid corticosteroid treatment for patients 
with severe pneumonia halted clinical and radiographic 
exacerbation and possibly prevented progression to 
ARDS in our series, further controlled clinical trials are 
needed to evaluate the role of corticosteroids for severely 
aﬀ  ected patients with inﬂ  uenza virus infections.
Abbreviation
ARDS, acute respiratory distress syndrome.
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Table 1. Clinical and laboratory characteristics of severe pneumonia patients infected with the 2009 H1N1 virus, with and 
without corticosteroid treatment
Group    With steroids (n = 17)  Without steroids (n = 15)  P value
Clinical characteristics
  Mean age, years  6.6 ± 1.5  7.8 ± 3.4  NS
 Males/Females,  number  13/4  12/3  NS
  Duration of fever, days
    Before admission  1.3 ± 0.5  1.3 ± 0.6  NS
    Total  2.1 ± 0.8  5.8 ± 4.8  0.009
  Hospitalization, days  6.4 ± 1.1  8.5 ± 7.0  NS
  Oxygen treatment, days  2.5 ± 0.6  5.1 ± 4.6  0.04
  Oseltamivir for less than 48 hours, number (percentage)a  17 (100)  13 (93)  NS
  Pneumonia, number (percentage)
    Segmental/Lobar  12 (71)  13 (87)  NS
    Progression after admission  5 (29)  4 (27)  NS
  Intensive care unit care, number (percentage)   0 (0)  4 (27)  0.02
  ARDS with ventilator, number (percentage)  0 (0)  2 (13)  NS
  Resolution of pneumonia, number (percentage)b   15 (88)  7 (43)  0.01
Laboratory fi  ndings
  Hemoglobin, g/dL  13.1 ± 1.0  13.2 ± 1.1  NS
  Leukocyte, × 109/L  11.8 ± 3.6  12.0 ± 5.0  NS
    Neutrophil, percentage  83.8 ± 8.0  86.2 ± 12.9  NS
    Lymphocyte, percentage  8.8 ± 6.3  7.4 ± 7.5  NS
    Monocyte, percentage  6.0 ± 2.3  5.0 ± 3.8  NS
  Platelet, × 109/L  268 ± 74  246 ± 53  NS
  C-reactive protein, mg/dL  3.0 ± 3.1  4.6 ± 3.9  NS
  Erythrocyte sedimentation rate, mm/hour  14 ± 8  15 ± 12  NS
Values are presented as mean ± standard deviation unless indicated otherwise. Laboratory fi  ndings were obtained at presentation. aNumber (percentage) of patients 
who received oseltamivir treatment within 48 hours of fever onset. bNumber (percentage) of patients who showed complete resolution of pneumonic infi  ltrations at 
discharge. ARDS, acute respiratory distress syndrome; NS, statistically non-specifi  c.
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